Donaldson Capital Management LLC Has $817,000 Holdings in Stryker Co. (NYSE:SYK)

Donaldson Capital Management LLC lessened its stake in Stryker Co. (NYSE:SYK) by 8.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,194 shares of the medical technology company’s stock after selling 190 shares during the quarter. Donaldson Capital Management LLC’s holdings in Stryker were worth $817,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in SYK. Capital & Planning LLC raised its stake in Stryker by 3.6% in the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after acquiring an additional 29 shares during the period. Brighton Jones LLC raised its stake in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the period. Empowered Funds LLC raised its stake in Stryker by 17.5% in the 4th quarter. Empowered Funds LLC now owns 7,644 shares of the medical technology company’s stock valued at $2,752,000 after acquiring an additional 1,140 shares during the period. Entropy Technologies LP bought a new stake in Stryker in the 4th quarter valued at $236,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in Stryker in the 4th quarter valued at $52,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. Truist Financial increased their price objective on Stryker from $390.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, May 5th. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research report on Friday, June 6th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Finally, Citigroup reiterated a “buy” rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $427.30.

Stryker Stock Down 1.0%

Shares of NYSE SYK opened at $381.03 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market capitalization of $145.43 billion, a P/E ratio of 49.10, a PEG ratio of 2.93 and a beta of 0.91. The stock’s fifty day moving average is $371.23 and its 200 day moving average is $375.95.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. Stryker’s revenue was up 11.9% compared to the same quarter last year. During the same period last year, the firm posted $2.50 earnings per share. Sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 45.41%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director now directly owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.